Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Single-epitope T cell–based vaccine protects against SARS-CoV-2 infection in a preclinical animal model
Takuya Tada, Ju-Yi Peng, Belinda M. Dcosta, Nathaniel R. Landau
Takuya Tada, Ju-Yi Peng, Belinda M. Dcosta, Nathaniel R. Landau
View: Text | PDF
Research Article COVID-19 Immunology

Single-epitope T cell–based vaccine protects against SARS-CoV-2 infection in a preclinical animal model

  • Text
  • PDF
Abstract

Currently authorized COVID-19 vaccines induce humoral and cellular responses to epitopes in the SARS-CoV-2 spike protein, though the relative roles of antibodies and T cells in protection are not well understood. To understand the role of vaccine-elicited T cell responses in protection, we established a T cell–only vaccine using a DC-targeted lentiviral vector expressing single CD8+ T cell epitopes of the viral nucleocapsid, spike, and ORF1. Immunization of angiotensin-converting enzyme 2–transgenic mice with ex vivo lentiviral vector–transduced DCs or by direct injection of the vector induced the proliferation of functional antigen-specific CD8+ T cells, resulting in a 3-log decrease in virus load upon live virus challenge that was effective against the ancestral virus and Omicron variants. The Pfizer/BNT162b2 vaccine was also protective in mice, but the antibodies elicited did not cross-react on the Omicron variants, suggesting that the protection was mediated by T cells. The studies suggest that the T cell response plays an important role in vaccine protection. The findings suggest that the incorporation of additional T cell epitopes into current vaccines would increase their effectiveness and broaden protection.

Authors

Takuya Tada, Ju-Yi Peng, Belinda M. Dcosta, Nathaniel R. Landau

×

Figure 3

Enhancement of the antiviral response by CD40L.

Options: View larger image (or click on image) Download as PowerPoint
Enhancement of the antiviral response by CD40L.
(A) The schematic diagra...
(A) The schematic diagram of lentiviral vectors expressing nonfunctional CD40L. The red asterisk indicates the T146N mutation in CD40L. (B) SAMHD1-KO BMDCs were transduced (MOI = 5) with lentiviral vectors expressing CD40L, mutated CD40L, CD40L-N219-227, and CD40L.T146N-N219-227 virus. After 3 days, the cells were analyzed for CD83 and CD86 by flow cytometry. (C) Mice were injected twice with transduced BMDCs and challenged with SARS-CoV-2 WA1/2020. After 3 days, virus load in the lung was measured by RT-qPCR. (D) Antigen-specific CD8+ T cells, IFN-γ in TCR+CD8+ T cells, and CD69+ cells in the immunized and challenged mice were quantified by flow cytometry. Statistical significance was determined by Kruskal-Wallis test with post hoc Dunn’s test. Confidence intervals are shown as the mean ± SD. (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.) The experiment was done twice with similar results.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts